Diabetes Remote Intervention to improVe Use of Evidence-based Medications

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT06046560

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06046560
Main results
  • Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial Circulation, 2024-06-04 DOI, PubMed 38583146
Other papers using this trial's data
  • Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk American heart journal, 2026-06 DOI, PubMed 41610902

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06046560. Randomized; no masking; primary purpose prevention. Start 2021-03-22 (actual); primary completion 2023-07-25 (actual). Results posted on 2024-10-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Diabetes Remote Intervention to improVe Use of Evidence-based Medications
Acronym
DRIVE
Condition
Cardiovascular Diseases
Condition
Diabetes
Intervention (Drug)
SGLT2 inhibitor, GLP-1 RA
Intervention (Behavioral)
Education-First
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06046560
Content hash
aa2ee4b4c844fdc8f93da9b1479537fe119e5acb586d517e9700c75b1a6c4316